Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at April 30, 2015

PARIS--()--Regulatory News:

Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority):

Date  

Total number of
outstanding shares

  Total number of voting rights
April 30, 2015   40, 544, 204  

Theoretical number of voting rights: 40, 544, 204
(including treasury shares)

Number of real voting rights: 40, 518, 878 (without
treasury shares)

About Onxeo
Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO) has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.

Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Positive preliminary results of the Phase II trial in severe oral mucositis
Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma
For more information, visit the website www.onxeo.com

Contacts

Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Caroline Carmagnol, Alize RP
onxeo@alizerp.com
+33 6 64 18 99 59 / +33 1 44 54 36 62

Contacts

Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Caroline Carmagnol, Alize RP
onxeo@alizerp.com
+33 6 64 18 99 59 / +33 1 44 54 36 62